Drug intelligence / Profile preview

E0714

Development stage: Preclinical
Lead developer: Hebei Medical University

Overview

E0714: sourced facts only. name: "Electrophysiology assays demonstrated that E0714 potently activates Kv7.2 without significantly affecting Kv7.1, Kv7.3, Kv7.4, or Kv7.5." [PMID:41711326]; target: "Electrophysiology assays demonstrated that E0714 potently activates Kv7.2 without significantly affecting Kv7.1, Kv7.3, Kv7.4, or Kv7.5." [PMID:41711326]; developer: "School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China." [PMID:41711326]; stage: "E0714 exhibited an excellent antiepileptic effect in classical epilepsy models without causing motor coordination problems." [PMID:41711326]

Targets

KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)

Beyond the preview

Go deeper on E0714.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E0714.